<DOC>
	<DOC>NCT01571648</DOC>
	<brief_summary>The purpose of this study is to evaluate the tolerability of oral azacitidine in the treatment of patients with Myelodysplastic Syndromes (MDS).</brief_summary>
	<brief_title>A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients must satisfy the following criteria to be enrolled in the study: Have a documented diagnosis of myelodysplastic syndromes (MDS) according to World Health Organization (WHO) 2008 classification Age â‰¥ 20 years; Written informed consent; Eastern Cooperative Oncology Group (ECOG) performance status of 02; Resolution of any toxic effects of prior anticancer therapy; and Negative urine or serum pregnancy test on females of childbearing potential. The presence of any of the following will exclude a patient from enrollment: Treatment with chemotherapy, radiotherapy, or surgery within 4 weeks of study registration; Pregnant or breastfeeding females; Previous or concomitant malignancy other than MDS; Significant active cardiac disease within the previous 6 months; Uncontrolled systemic infection or Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>